PLANT & INFRASTRUCTURENo sanctions match · screened 20 Nov 2026

Abbott Laboratories

abbott.comUpdated 8 Nov 2026

Strategic intent

Abbott Laboratories is a global healthcare company that develops, manufactures, and sells medical devices, diagnostic systems, pediatric and adult nutritional products, and branded generic pharmaceuticals.

Key market signals

  • 2026-11: Abbott announced positive late-breaking clinical data at the TCT conference for its investigational Amulet 360 LAA occluder and SonicForce coronary lithotripsy system.
  • 2026-10: Abbott announced a major strategic plan to spin off its $8.5 billion Nutrition business into an independent publicly traded company by the end of 2027, to be led by Daniel Salvadori.
  • 2026-09: Abbott agreed to pay $385 million to settle DOJ False Claims Act allegations regarding manufacturing noncompliance at its infant formula facilities.
  • 2026-08: Abbott entered into agreements to pay approximately $670 million to resolve the Gill v. Abbott Laboratories lawsuit and NEC claims involving approximately 2,000 additional infants.
  • 2026-03: Abbott completed its $20.6 billion acquisition of Exact Sciences, funded primarily by issuing $20.0 billion of long-term debt, establishing its new Cancer Diagnostics business segment.

Financial health

  • For the first nine months of 2026, Abbott reported net sales of $36.770 billion (up from $32.869 billion in 9M25) and net earnings of $2.925 billion (down from $4.748 billion in 9M25) due to litigation charges. (https://www.sec.gov)
  • Operating cash flow for the first nine months of 2026 was $5.540 billion, compared to $6.251 billion in the prior year period. (https://www.sec.gov)
  • As of September 30, 2026, Abbott held cash and equivalents of $4.052 billion and long-term debt of $29.451 billion, which increased from $9.896 billion at year-end 2025 due to funding the $20.6 billion acquisition of Exact Sciences. (https://www.sec.gov)

Impact & compliance

Social ImpactModern Slavery Statement (2025)Scope 3 data: comprehensiveThird-party assured

Proprietary analysis

  • Strategic fit

    AI-calculated strategic alignment score

    Log in to see
  • Cultural fit

    Trust and integrity score

    Log in to see
  • Alignment dimensions

    How this supplier scores against each of your strategic imperatives

    Log in to see
  • Full forensic analysis

    Complete ESG audit, modern slavery risk assessment, labour sentiment analysis, and observed contradictions with evidence trails.

    Log in to see

Want the full analysis?

Strategic and cultural fit scoring, full forensic detail and alignment dimensions, for this supplier and your own.